NY-BR-1 protein expression in breast carcinoma: a mammary gland differentiation antigen as target for cancer immunotherapy by Theurillat, Jean-Philippe et al.
Cancer Immunol Immunother (2007) 56:1723–1731 
DOI 10.1007/s00262-007-0316-1
ORIGINAL ARTICLE
NY-BR-1 protein expression in breast carcinoma: a mammary 
gland diVerentiation antigen as target for cancer immunotherapy
Jean-Philippe Theurillat · Ursina Zürrer-Härdi · Zsuzsanna Varga · Martina Storz · Nicole M. Probst-Hensch · 
Burkhardt Seifert · Mathias K. Fehr · Daniel Fink · Soldano Ferrone · Bernhard Pestalozzi · 
Achim A. Jungbluth · Yao-Tseng Chen · Dirk Jäger · Alexander Knuth · Holger Moch 
Received: 17 November 2006 / Accepted: 10 March 2007 / Published online: 5 April 2007
©  Springer-Verlag 2007
Abstract NY-BR-1 is a recently identiWed diVerentiation
antigen of the mammary gland. To use NY-BR-1 for T-
cell-based immunotherapy, analysis of its co-expression
with HLA class I antigens is required. In the present tissue
microarray study, primary breast cancers (n = 1,444), recur-
rences (n = 88), lymph node (n = 525) and distant metasta-
ses (n = 91) were studied for NY-BR-1 expression using
a novel monoclonal antibody. NY-BR-1 expression was
compared with prognosis, estrogen receptor, HER2-status,
EGFR and HLA class I antigen expression. NY-BR-1 was
more frequently expressed in grade 1 (82%) than in grade 2
(69%) and grade 3 (46%) carcinomas (P < 0.0001). More-
over, NY-BR-1 expression correlated directly with estrogen
receptor expression (P < 0.0001) and inversely correlated
with HER2-status and EGFR expression (P < 0.0001 for
both). Considering high expression level of co-expression,
198/1,321 (15%) primary breast carcinomas and 4/65 (6%)
distant metastases expressed NY-BR-1 and HLA class I,
suggesting that active immunotherapy can be applied to
about 10% of breast cancer patients. Survival analysis
showed an association of NY-BR-1 expression with better
patient outcome (P = 0.015). No diVerence between NY-
BR-1 expression of primary tumors and metastases could
be found, indicating that the presence of NY-BR-1 in
metastases can be deduced from their corresponding
primary. Forty-three paired biopsies taken from patients
before and after chemotherapy suggest that NY-BR-1
expression is not inXuenced by preceding chemotherapy
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1724 Cancer Immunol Immunother (2007) 56:1723–1731NY-BR-1 with HLA class I antigens and its expression in
metastases without modiWcation by chemotherapy suggest
that NY-BR-1 targeted immunotherapy represents a viable
strategy in addition to other targeted cancer drug therapies
of breast cancer.
Keywords NY-BR-1 · Breast cancer · Immunotherapy · 
Immunohistochemistry · Tissue microarray · HLA class I
Introduction
Targeted cancer drugs, e.g., trastuzumab against HER2 or
geWtinib against EGFR, have been proven to be a novel
eVective strategy for cancer treatment [1, 2]. T-cell-based
immunotherapy targeting antigens such as cancer testis
(CT) antigens or diVerentiation antigens is another promis-
ing new treatment modality, which is currently being tested
in clinical trials [3–7]. Both targeted cancer drugs and T-
cell-based immunotherapy display target speciWcity against
cancer cells, thus reducing undesired eVects as encountered
with conventional cancer chemotherapy. The expression of
an optimal target for tumor immunotherapy should be
restricted to or at least selective in malignant lesions.
Examples are CT antigens or diVerentiation antigens that
remain stable during disease progression [8].
Recently, we have identiWed the NY-BR-1 gene by
SEREX analysis (serological analysis of recombinant
expression libraries) of a patient with metastatic breast car-
cinoma and we have shown that about 10% of the patients
with NY-BR-1 positive tumors exhibited a humoral
immune response to NY-BR-1 [8, 9]. In addition, others
and we recently identiWed two HLA-A2 restricted epitopes
that are recognized by CD8 positive T-cells [10, 11]. Both
epitopes are naturally processed and presented. The NY-
BR-1 gene is located on chromosome 10p11-p12 and is
composed of 37 exons. It encodes a peptide of Mr 150,000–
160,000, a putative transcription factor. Since its protein
expression is restricted to normal and neoplastic breast epi-
thelium, NY-BR-1 is classiWed as a diVerentiation antigen
of the mammary gland. A recent immunohistochemical
study with a limited number of breast carcinoma lesions has
shown that NY-BR-1 is expressed in about 60% of breast
carcinoma and has conWrmed the breast epithelium speci-
Wcity [12]. Due to this organ-speciWcity, NY-BR-1 repre-
sents an attractive target for cancer immunotherapy and can
be potentially used for diagnostic purposes in surgical
pathology.
To explore NY-BR-1 as a potential target for cancer
immunotherapy of breast cancer, more knowledge about
the NY-BR-1 expression on a protein level in a larger
cohort of primary tumors and distant metastases is para-
mount. Also, potential associations with clinical parameters
and other markers such as estrogen receptor (ER) and
progesterone receptor (PR) are necessary. Furthermore, for
T-cell mediated immunization strategies, major histocom-
patibility complex (HLA) class I is required for presenta-
tion of target antigens, mediating the recognition of tumor
cells by cytotoxic T-cells. Therefore, data about the pres-
ence of HLA class I and NY-BR-1 co-expression is crucial
[13, 14].
Consequently, in the present study we determined the
protein expression of NY-BR-1 in a large number of
primary breast carcinomas, lymph node and distant metas-
tases by immunohistochemistry using tissue microarrays
(TMA). NY-BR-1 expression was correlated with progno-
sis, predictive parameters, e.g., ER, epidermal growth
factor receptor (EGFR) and HER2-gene ampliWcation as
well as with HLA class I expression. Furthermore, we
also analyzed the impact of chemotherapy on NY-BR-1
expression.
Materials and methods
Patients and tissues
Formalin-Wxed paraYn-embedded tissue samples from
patients of the University Hospital Zurich between 1991
and 2005 were retrieved from the archives of the Institute
of Surgical Pathology. This project was approved by the
local Commission of Ethics (ref. no. StV 12-2005). The
mean age of the patients at diagnosis was 60.4 years (range
15–98). Twenty-Wve percent of the patients were pre-meno-
pausal and 75% post-menopausal. H&E stained sections of
all tumors were re-evaluated by one pathologist (J.P.T.) for
suitability for TMA construction. The construction of TMA
has been previously described [15]. The following tissues
were arrayed into seven paraYn TMAs: 144 normal breast
tissues, 148 carcinoma in situ lesions, 1,444 primary inva-
sive carcinomas, 88 local recurrences, 525 lymph node
metastases and 91 distant metastases. The primary carcino-
mas consisted of 1,135 (78.6%) invasive ductal and 217
(15.0%) invasive lobular carcinomas, according to the
WHO tumor classiWcation. Other tumor types (6.4%)
included invasive tubular, cribriforme, medullary, mucin-
ous, apocrine, metaplastic, glycogen-rich clear cell, micro-
papillary and papillary carcinomas.
According to TNM criteria 706 tumors were pT1, 685
pT2, 105 pT3 and 150 pT4. A total of 414 tumors were
pN0, 604 pN1 and 168 pN2/pN3. The pT-category and the
pN-category could not be established for 12 and 427 cases,
respectively. Histopathological grading was performed
according to the modiWed Bloom and Richardson system
[16]. Two hundred and four primary tumors were grade 1
(82%), 708 grade 2 (69%) and 490 grade 3 (46%).123
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from the Cancer Register, Zurich. Additional data were
obtained from the Department of Gynecology and the
Department of Oncology of the University Hospital,
Zurich.
To determine the impact of chemotherapy on NY-BR-1
expression, large paraYn sections from a previously
described cohort of 43 patients were analyzed [17]. Tumor
tissue before and 6 months after neoadjuvant chemotherapy
was investigated for NY-BR-1 expression in each of these
patients.
Immunohistochemistry
For initial analysis, immunostaining of monoclonal anti-
body (mAb) NY-BR-1 was adjusted to the Ventana Bench-
mark system by performing titrations and initial reactivity
assessment in a small series of invasive breast cancer sam-
ples as previously described [12].
ER and EGFR expression was detected using the Ven-
tana Benchmark (Ventana Medical Systems, Tucson, AZ,
USA) automated stainer according to the manufacturer’s
recommendations with mAbs 6F11 (Ventana) against estro-
gen receptor and mAbs 3C6 (Ventana) against EGFR.
For the analysis of HLA class I expression mAb HC-
10 (1:100) was used, which recognizes a determinant
expressed on virtually all ß2m-free HLA-B heavy chains
and on ß2m-free HLA-A10, HLA-A28, HLA-A29, HLA-
A30, HLA-A31, HLA-A32, and HLA-A33 heavy chains
[18].
TMAs were analyzed with the Ventana Benchmark auto-
mated staining system (Ventana) using Ventana reagents
for the entire procedure. For antigen retrieval, slides were
heated with cell conditioning solution (CC1) in a standard
protocol. Endogenous peroxidase was blocked using the
Ventana endogenous peroxidase blocking kit.
The immunohistochemical reactivity for all antibodies
was measured as percentage of positive cells per spot (0, 5,
10, 20%, etc.), regardless of the intensity of staining. Apart
from survival analysis and examination of NY-BR-1
expression before and after chemotherapy, all statistical
procedures were based on percentage of positive cells per
spot. For multivariate analysis, staining was categorized
into positive (¸5% positive cells) and negative (<5% posi-
tive cells). For survival curves, kappa analysis and tables
we used the following simpliWed scoring system for NY-
BR-1: negative (0% positive cells), weak (1–70%), strong
(>70%). ER and EGFR stains were considered as positive
when at least 5% of the tumor cells or more were positive.
The expression of HLA class I was scored in three groups:
negative (0–25%), heterogeneous (26–75%) and positive
(>75% positive tumor cells), as it has been recently
described [19].
The status of the HER2-neu proto-oncogene was
assessed on TMAs by Xuorescence in situ hybridization
(FISH) using direct Xuorescent-labeled DNA probes
obtained from Pathvysion (VYSIS, Abott AG Diagnostic
Division, Baar, Switzerland) and an Olympus microscope.
The interpretation of the Xuorescence signals was carried
out according to the manufacturer’s recommendations.
Presence of Wve or more HER2-neu copy number signals
was deWned as ampliWcation.
Statistics
Categorical data were compared using chi-square test. The
Spearman rank correlation was used to correlate continuous
(NY-BR-1, ER, EGFR and HLA class I immunohistochem-
istry) as well as ordinal clinicopathological parameters
(stage and grade). DiVerences of continuous parameters
(NY-BR-1) between groups (menopausal and HER2-status)
were analyzed using the Mann–Whitney test. To determine,
expression diVerences within the same patient, Wilcoxon
signed rank test was used. A measure of agreement ( anal-
ysis) was done to analyze the congruence of NY-BR-1
expression before and after neoadjuvant chemotherapy.
Overall survival was calculated using Kaplan–Meier
curves with assessment of statistical signiWcance using log-
rank test. Univariate and stepwise (backwards) Cox propor-
tional-hazard regression was used to determine hazard
ratios and independent risk factors. Results were considered
statistically signiWcant if P values were 0.05 or less.
Results
NY-BR-1 protein expression in primary breast carcinoma 
lesions 
Figure 1 shows representative positive and negative immu-
nohistochemical stainings for NY-BR-1, EGFR, ER and
HLA class I. In our study we found NY-BR-1 expressed in
63.5% of all primary invasive carcinomas (Table 1). NY-
BR-1 was expressed in 80.7% of ductal carcinoma in situ
(DCIS) and lobular carcinoma in situ (LCIS). The inci-
dence of NY-BR-1 expression was signiWcantly higher
in lobular lesions (LCIS 100%; invasive lobular cancer
73.8%, respectively) than in ductal lesions (DCIS 78.6%;
invasive ductal cancer 61.1%, respectively; P = 0.0006).
A heterogeneous weak to strong NY-BR-1 staining was
observed in the epithelium of normal breast specimens, as
described in our previous study [12]. A similar expression
pattern was also present on all large tissue sections of
lactating breast (n = 10).
Table 2 gives a summary of the association of NY-BR-1
protein expression with established prognostic factors.123
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cal markers were due to tissue damage (either tissue loss or
inadequate tumor tissue) a problem associated with TMAs.
NY-BR-1 protein expression was signiWcantly associated
with tumor grade (P < 0.0001), but was not associated with
tumor stage (pT- and pN-category) or bilaterality/multifo-
cality (data not shown).
Apart from tumor grade, NY-BR-1 expression correlated
signiWcantly with ER expression (P < 0.0001): 70.1% of the
ER-positive tumors also co-expressed NY-BR-1, whereas
over 66% of the ER-negative tumors were also negative
for NY-BR-1.
NY-BR-1 expression inversely correlated to both HER2
ampliWcation and EGFR expression (P < 0.0001 each;
Table 2), since NY-BR-1 was expressed in 65% of tumors
without HER2 ampliWcation and in 67.4% of EGFR nega-
tive tumors.
Since HLA class I molecule expression on tumor cells is
crucial for their recognition by T-cells, we screened the
breast carcinoma lesions for NY-BR-1/HLA class I co-
expression. Table 3 gives a summary of the association of
NY-BR-1 protein expression and HLA class I expression.
Among primary breast carcinomas, 587 out of 1,321 (44%)
expressed at least heterogeneously HLA class I and weakly
NY-BR-1. A similar expression level of both antigens was
present in 163/470 (35%) lymph node metastases, 20/78
(25%) recurrences, and in 17/65 (26%) distant metastases.
Corresponding strong expression levels of NY-BR-1 and
HLA class I (both more than 70% of the tumor cells) was
present in 198/1,321 (15%) primaries, 45/470 (10%) lymph
Fig. 1 DiVerential expression 
of NY-BR-1, estrogen receptor 
(ER), EGFR and HLA class I 
heavy chain in breast carcinoma 
lesions by immunohistochemis-
try using mAbs. The staining for 
NY-BR-1 was nuclear/cytoplas-
mic, for ER nuclear, for EGFR 
membraneous/cytoplasmic and 
for HLA class I predominantly 
membranous. Only stromal and 
inXammatory cells were stained 
in negative tumor lesions
Table 1 NY-BR-1 expression 
in breast lesions (the numbers 
in the tables are related to the 
number of interpretable spots 
on the tissue microarray)
NY-BR-1 expression
Tissue type Negative Weakly positive Strongly positive
n n Percent n Percent n Percent
Normal tissue 68 6 8.8 54 79.4 8 11.8
In situ lesions
All 145 28 19.3 31 21.4 86 59.3
DCIS high grade 44 12 27.3 9 20.5 23 52.3
DCIS non high grade 87 16 18.4 18 20.7 53 60.9
LCIS 14 0 0 4 28.6 10 71.4
Invasive cancer
All 1,367 499 36.5 335 24.5 533 39
Ductal 1,085 421 38.8 249 22.9 415 38.2
Lobular 195 51 26.2 65 33.3 79 40.5
Others 86 27 31.4 21 24.4 38 44.2
Recurrences 79 40 50.6 21 26.6 18 22.8
Lymph node metastases 490 195 39.8 105 21.4 190 38.8
Distant metastases 67 32 47.8 15 22.4 20 29.9123
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distant metastases.
NY-BR-1 protein expression in recurrences and metastases
The NY-BR-1 expression in lymph node metastases
(60.2%) was comparable to that in primary tumors (63.5%)
but decreased to 52.2 and 49.4% in distant metastases and
recurrences, respectively (Table 1). The lower NY-BR-1
expression in metastases than in primary lesions prompted
us to compare NY-BR-1 expression in individual primary
tumors and their corresponding metastases. A signiWcant
correlation was found between NY-BR-1 expression in
primary tumors and their corresponding lymph node
metastases (P < 0.0001) as well as in primary tumors
and their corresponding distant metastases and recurrences
(P = 0.0002, 0.0045, respectively). Fifteen out of 17 (88%)
NY-BR-1 weakly and strongly positive primary tumours
expressed NY-BR-1 in their corresponding recurrence,
whereas two initially positive tumours were negative in
recurrences. Ten out of 14 (71%) NY-BR-1 weakly and
strongly positive primary tumours expressed also NY-BR-1
in their corresponding distant metastasis (data not shown).
Comparison of immunohistochemical reactivity of NY-BR-
1 (as described in “Materials and methods”) between pri-
mary tumors and lymph node metastasis (n = 406) revealed
no statistical diVerences (P = 0.10). The immunohisto-
chemical reactivity of NY-BR-1 was decreased in distant
metastases (n = 36); this diVerence, however, did not reach
the level of statistical signiWcance. In contrast, the immuno-
histochemical reactivity of NY-BR-1 was signiWcantly
decreased in recurrences when compared to their primary
counterparts (P = 0.019).
NY-BR-1 expression and patient prognosis
Preliminary data evaluated the quality of our survival data
by correlating survival analyses with established prognostic
factors. Low tumor grade, small tumor size, negative lymph
node status, positive ER-status as well as negative EGFR
Table 2 NY-BR-1 expression 
in primary invasive breast 
cancer according to clinico-
pathological variables
NY-BR-1 expression
na Negative Weakly positive Strongly positive P value
n Percent n Percent n Percent
Histologic grade
G1 (well diVerentiated) 210 36 17.1 65 31.0 109 51.9 <0.0001b
G2 (moderately diVerentiated) 667 202 30.3 171 25.6 294 44.1
G3 (poorly diVerentiated) 469 256 54.6 92 19.6 121 25.8
pT-category
pT1 535 165 30.8 151 28.2 219 40.9 NSb
pT2 602 238 39.5 124 20.6 240 39.9
pT3 89 36 40.4 28 31.5 25 28.1
pT4 134 57 42.5 31 23.1 46 34.3
pN-category
pN0 212 82 38.7 52 24.5 78 36.8 NSb
pN0 (SN) 118 34 28.8 37 31.4 47 39.8
pN1 510 206 40.4 122 23.9 182 35.7
pN2/3 149 56 37.6 38 25.5 55 36.9
Menopausal status
Premenopausal 261 99 37.9 67 25.7 95 36.4 NSc
Postmenopausal 905 332 36.7 218 24.1 355 39.2
Estrogen receptor status
Negative 245 164 66.9 40 16.3 41 16.7 <0.0001b
Positive 1,105 330 29.9 293 26.5 482 43.6
HER2 gene ampliWcation
Not ampliWed 1,152 404 35.1 283 24.6 465 40.4 <0.0001c
AmpliWed 169 81 47.9 39 23.1 49 29
EGFR expression
Negative 1,061 346 32.6 263 24.8 452 42.6 <0.0001b
Positive 275 139 50.5 63 22.9 73 26.5
SN sentinel (if applicable)
NS not signiWcant
a DiVerences in the number of 
cases among immunohistochem-
ical markers was due to tissue 
damage (either tissue loss 
or inadequate tumor tissue) 
a problem associated with 
tissue microarrays
b Spearman rank correlation
c Mann–Whitney test123
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ated with improved clinical outcome in our patients
(P < 0.0001, each; data partly shown in Fig. 2 and Table 4).
Patients with strong NY-BR-1 expression had a better
prognosis than patients with NY-BR-1 negative tumors
(P = 0.008; data not shown). The 5-year overall survival for
patients with strong expression was 83% compared to 74%
for patients with NY-BR-1 negative tumors. Interestingly,
when all patients were considered, those with weak NY-
BR-1 expression in their tumors resembled those with
strong NY-BR-1 expression in the favorable clinical course
of the disease. However, when only pre-menopausal
patients were considered, those with weak NY-BR-1
expression in their tumors resembled those with NY-BR-1
negative tumor in the poor outcome of the disease (Fig. 2).
An additional analysis showed that this eVect was due to an
increased number of high grade tumors with weak NY-BR-
1 positivity in the pre-menopausal group.
Multivariate analysis conWrmed pT category, lymph
node status, tumor grade and EGFR as well as HER2 gene-
status to be independent prognostic markers (Table 4). NY-
BR-1 expression and ER-status are both linked to grading
and were therefore not independent prognostic variables.
HLA class I expression was not associated with patient out-
come in uni- and multivariate analyses.
EVect of chemotherapy on NY-BR-1 expression 
To test whether chemotherapy could have an eVect on NY-
BR-1 expression, we analyzed 43-paired biopsies taken
from patients just before starting neoadjuvant chemother-
apy and 6 months after having received neoadjuvant che-
motherapy. Seventeen patients received anthracyclines, two
taxane and seventeen anthracyclines combined with tax-
anes. The type of chemotherapy could not be determined
for the remaining seven patients. NY-BR-1 expression by
IHC in paired biopsies was categorized into negative,
weakly and strongly positive (as described in “Materials
and methods”). The staining pattern of the biopsies
obtained before and after therapy was not diVerent in 40
(93%) of the 43 patients investigated ( = 0.89, P < 0.0001;
95% CI 81–99%). In this group, nine tumors were negative
for NY-BR-1, 16 tumors expressed weakly and 15 strongly
NY-BR-1. However, NY-BR-1 could not be detected in the
biopsies obtained from two (4%) patients after chemother-
apy with initially weakly and strongly positive tumors. The
latter two patients had both received anthracycline-contain-
ing chemotherapies. Initial absence of NY-BR-1 expression
was observed in one patient (2%), showing weak levels of
NY-BR-1 in the tumor cells after chemotherapy. The type
of chemotherapy could not be determined for this patient.
Discussion
In agreement with our recent immunohistochemical results
obtained from 124 breast carcinoma lesions [12], the pres-
ent study of more than 2,000 breast carcinoma lesions with
a recently developed mAb has shown that NY-BR-1 is a
breast epithelium diVerentiation antigen. Its expression is
Table 3 NY-BR-1 and HLA class I expression in primary tumors, recurrences, lymph node and distant metastases
NY-BR-1 expression
n Negative Weakly positive Strongly positive
n Percent n Percent n Percent
(a) HLA class I expression in primary tumors 
Negative 408 163 40 81 19.9 164 40.2
Heterogeneous 365 127 34.8 80 21.9 158 43.3
Positive 548 199 36.3 151 27.6 198 36.1
(b) HLA class I expression in reccurrences 
Negative 33 15 45.5 8 24.2 10 30.3
Heterogeneous 16 8 50 3 18.8 5 31.3
Positive 29 17 58.6 9 31 3 10.3
(c) HLA class I expression in lymph node metastases 
Negative 192 72 37.5 38 19.8 82 42.7
Heterogeneous 138 50 36.2 33 23.9 55 39.9
Positive 140 65 46.4 30 21.4 45 32.1
(d) HLA class I expression in distant metastases
Negative 33 17 51.5 8 24.2 8 24.2
Heterogeneous 20 8 40 5 25 7 35
Positive 12 7 58.3 1 8.3 4 33.3123
Cancer Immunol Immunother (2007) 56:1723–1731 1729associated with tumor diVerentiation, HER2-gene, EGFR
and ER-status of breast cancer and prognosis. On large sec-
tions, we have observed that NY-BR-1 expression is heter-
ogeneous in primary tumors [12]. Despite this intratumoral
heterogeneity, the frequency of NY-BR-1 positive primary
tumors on TMAs was comparable to that derived from
large tissue section analysis. This indicates that the mic-
roarrray approach is suitable even when analyzing the
expression of markers with a heterogeneous expression,
because the large numbers of tumors compensate the small
size of tissue samples [20, 21]. Due to its HLA class I co-
expression and its stable expression in distant metastases
NY-BR-1 appears to be a promising target for T-cell-based
immunotherapy and vaccination strategies.
The present study has shown that multivariate analysis
did not identify NY-BR-1 expression as an independent
prognostic marker. In univariate analysis, strong NY-BR-1
expression is associated with a good prognosis due to the
strong association of NY-BR-1 expression with tumor
grade. Weak NY-BR-1 expression is associated with poor
prognosis in pre-menopausal but not in postmenopausal
patients. This Wnding can be explained by the larger number
of high grade tumors in the group of pre-menopausal
patients.
Like several other diVerentiation antigens, NY-BR-1
has a lower expression in metastatic lesions, because
tumors of higher histological grade are more likely to
metastasize. SpeciWcally NY-BR-1 expression decreases in
the following order: carcinoma in situ (CIS) > invasive
carcinoma > lymph node metastasis > distant metastasis.
However, analysis of autologous primary and metastatic
lesions of a particular patient showed a high concordance in
NY-BR-1 expression in primary tumors and the corre-
sponding lymph node metastases. Even distant metastases
were found not to diVer signiWcantly from autologous pri-
mary tumors in NY-BR-1 expression level. Taken together,
these results suggest that NY-BR-1 expression remains sta-
ble during disease progression. This Wnding is of particular
interest, since therapeutic decisions in metastatic cancer are
often based on the presence of biomarkers assessed solely
in the primary tumor as it is almost always the case for the
HER2-gene-status [17, 21, 22].
Cancer immunotherapy is potentially applied as an addi-
tional therapeutic strategy in combination with conven-
tional chemo- or endocrine therapy. Therefore, knowledge
about the relation of NY-BR-1 to other established thera-
peutic target antigens is crucial. According to our data, NY-
BR-1 is present in a large number of tumors without EGFR/
HER2 expression, suggesting that NY-BR-1 immunother-
apy is a potential treatment option for patients with such
tumors.
Breast cancer treatment largely depends on the hormone
receptor status. Interestingly, NY-BR-1 expression was not
associated to menopausal status, suggesting that estrogen
levels might not inXuence NY-BR-1 expression to a large
extent. However, the signiWcant reduction of NY-BR-1
expression in local recurrences, especially when only
Fig. 2 Overall survival analysis according to NY-BR-1 expression in
all patients (a), in premenopausal patients (b), and in all patients
according to diVerentiation grade (c) and estrogen receptor (ER) status
(d)123
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compatible with the possibility that estrogen antagonists
might negatively aVect NY-BR-1 expression (Theurillat
et al., submitted). This possibility should be taken into
account when evaluating NY-BR-1 as a target for immuno-
therapy.
An increasing body of evidence suggests that modiWca-
tion of the EGFR/HER2 signaling pathway by targeted can-
cer drugs oVers novel treatment options for breast cancer.
Trastuzumab against HER2 has been shown to be eVective
as an adjuvant therapy in combination with chemotherapy
[1, 2]. Recent clinical observations suggested that EGFR-
signaling-inhibitors might restore anti-estrogene-sensi-
tivity after tamoxifen-acquired resistance [23, 24]. Our
previous study comprising a limited number of breast
cancer lesions (n = 124) revealed a weak linear correlation
between NY-BR-1 expression and HER2-amplication [12].
Sixty-nine percent of the primary breast cancer co-
expressed NY-BR-1. In contrast, in the present study we
found an inverse correlation between HER2/EGFR expres-
sion and NY-BR-1. This discrepancy is due to the fact that
the former study included a much higher percentage of
poorly diVerentiated, HER2-ampliWed tumors (percentage
of HER2-ampliWcation 57 vs. 14%). The much higher num-
ber of tumors and a prevalence of HER2-ampliWcation,
which is comparable to the literature [25] indicate that the
present results are more informative. Despite a weak
inverse correlation, we found in the present study a co-
expression of NY-BR-1 in about 50% of HER2-ampliWed
as well as in EGFR positive carcinomas. Therefore, active
speciWc immunotherapy targeting NY-BR-1 could be theo-
retically considered in combination to other targeted cancer
drugs as an early, possibly adjuvant treatment option.
Currently, active speciWc immunotherapy is mostly
applied in patients with metastatic disease, who have
already received chemotherapy in an adjuvant or rarely in a
neoadjuvant setting. Therefore it is important to know
whether chemotherapy could inXuence NY-BR-1 expres-
sion. Our data indicate that neoadjuvant chemotherapy may
have no eVect on NY-BR-1 expression, suggesting that
active speciWc immunotherapy targeting NY-BR-1 can be
considered even in patients who have been treated with sev-
eral chemotherapy cycles.
Successful implementation of T-cell-based immunother-
apy of malignant diseases requires that HLA class I antigens
are expressed on tumor cells and that they present tumor
antigen derived peptides HLA class I antigen restricted,
tumor antigen-speciWc cytotoxic T-cells [13, 14]. However,
abnormalities in HLA class I antigen expression and/or func-
tion and/or in antigen-processing machinery are frequently
found in human malignancies [26, 27]. Therefore knowledge
about NY-BR-1 and HLA class I antigen co-expression are
crucial, if T-cell based immunotherapy targeting NY-BR-1 is
considered. In 15% of primary breast carcinoma, a strong co-
expression of both antigens was observed. Although this fre-
quency of HLA class I/NY-BR-1 co-expression in primary
tumors is promising for T-cell-based immunotherapy,
clinical trials will be primarily implemented in patients
with metastatic disease. In distant metastases, NY-BR-1
and HLA class I was co-expressed to some extent in 26%
of the cases—however, we observed only in 6% a strong
co-expression of both antigens. The decreased level of co-
expression was mainly due to a decrease of HLA class
I expression observed during metastatic spread. Surprisingly,
uni- and multivariate analysis did not show an association of
HLA class I expression with prognosis in our patient cohort.
This Wnding is in contrast to Wndings of Madjd et al. [28]
recent results. The latter investigators identiWed HLA class I
antigen loss as an independent marker of good prognosis.
The discrepancy between Madjd et al. results and our own
are not likely to reXect diVerences in the methodology used
since in both studies TMA and mAb HC10 were utilized. A
more likely explanation for the conXicting results is repre-
sented by diVerences in the characteristics of the patient
populations investigated in the two studies.
In summary, we have demonstrated that NY-BR-1 meets
most, if not all the criteria required to be utilized as a target
for T-cell-based immunotherapy.
Table 4 Univariate and multi-
variate analyzes including pT- 
and pN-category, histologic 
grade, HER2 gene-status, 
EGFR, estrogen receptor, 
NY-BR-1 and HLA class I 
for overall survival
Variables Univariate multivariate
n Hazard ratio 
(95% CI)a
P value n Hazard ratio 
(95% CI)a
P value
pT 1,033 1.72 (1.54–1.92) <0.0001 728 1.78 (1.53–2.06) <0.0001
pN 740 1.61 (1.36–1.90) <0.0001 728 1.38 (1.15–1.65) 0.0005
Histologic grade 1,023 1.62 (1.34–1.96) <0.0001 728 1.46 (1.13–1.88) 0.003
EGFR 1,038 1.45 (1.12–1.87) 0.005 728 1.91 (1.39–2.61) 0.0001
HER2 gene-status 1,038 1.90 (1.41–2.57) 0.0001 728 1.59 (1.12–2.24) 0.009
Estrogen receptor 1,038 0.55 (0.42–0.72) 0.0001 728 – NS
NY-BR-1 1,038 0.74 (0.59–0.96) 0.015 728 – NS
HLA class I 1,038 – NS 728 – NS
NS not signiWcant
a increase of hazard for one 
stage (pT, pN, histologic grade) 
or negative to positive (EGFR, 
HER2-status, estrogen receptor, 
NY-BR-1, HLA class I)123
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